Wnt signaling pathway inhibitors as promising diagnostic serum markers of osteolytic bone metastasis

Research output: Contribution to journalArticle

Abstract

Despite the clinical importance of bone metastases, we still know little about their onset and progression and current diagnostic tools lack the sensitivity and specificity required for clear early diagnosis. We therefore need to continue studying the pathogenesis of bone metastatic invasion in order to improve diagnosis. The Wnt pathway has been described as having an important role in bone carcinogenesis and metastatic progression. This study investigated the diagnostic potential of the two main Wnt inhibitors, sclerostin and DKK-1, to improve the detection of osteolytic bone metastases. We measured sclerostin and DKK-1, MMP-2 and MMP-9, the bone resorption marker TRAP5b and the metastatic marker survivin in a control group of healthy patients, in patients with primary tumors and in a group with metastasis. Sclerostin and DKK-1 were clearly high in primary tumor patients and even higher in metastatic patients, compared to controls. The close correlations with metastatic markers and bone resorption markers make sclerostin and DKK-1 promising as new biomarkers in the diagnosis of bone osteolytic metastases.

Original languageEnglish
Pages (from-to)399-408
Number of pages10
JournalJournal of Biological Regulators and Homeostatic Agents
Volume30
Issue number2
Publication statusPublished - Apr 1 2016

Fingerprint

Wnt Signaling Pathway
Biomarkers
Neoplasm Metastasis
Bone and Bones
Bone Resorption
Matrix Metalloproteinases
Early Diagnosis
Neoplasms
Carcinogenesis
Sensitivity and Specificity
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{0d71964b802643619cca8b1eb8b13a76,
title = "Wnt signaling pathway inhibitors as promising diagnostic serum markers of osteolytic bone metastasis",
abstract = "Despite the clinical importance of bone metastases, we still know little about their onset and progression and current diagnostic tools lack the sensitivity and specificity required for clear early diagnosis. We therefore need to continue studying the pathogenesis of bone metastatic invasion in order to improve diagnosis. The Wnt pathway has been described as having an important role in bone carcinogenesis and metastatic progression. This study investigated the diagnostic potential of the two main Wnt inhibitors, sclerostin and DKK-1, to improve the detection of osteolytic bone metastases. We measured sclerostin and DKK-1, MMP-2 and MMP-9, the bone resorption marker TRAP5b and the metastatic marker survivin in a control group of healthy patients, in patients with primary tumors and in a group with metastasis. Sclerostin and DKK-1 were clearly high in primary tumor patients and even higher in metastatic patients, compared to controls. The close correlations with metastatic markers and bone resorption markers make sclerostin and DKK-1 promising as new biomarkers in the diagnosis of bone osteolytic metastases.",
author = "E. Galliera and Marazzi, {M. G.} and L. Drago and G. Banfi and A. Luzzati and {Corsi Romanelli}, {M. M.}",
year = "2016",
month = "4",
day = "1",
language = "English",
volume = "30",
pages = "399--408",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "2",

}

TY - JOUR

T1 - Wnt signaling pathway inhibitors as promising diagnostic serum markers of osteolytic bone metastasis

AU - Galliera, E.

AU - Marazzi, M. G.

AU - Drago, L.

AU - Banfi, G.

AU - Luzzati, A.

AU - Corsi Romanelli, M. M.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Despite the clinical importance of bone metastases, we still know little about their onset and progression and current diagnostic tools lack the sensitivity and specificity required for clear early diagnosis. We therefore need to continue studying the pathogenesis of bone metastatic invasion in order to improve diagnosis. The Wnt pathway has been described as having an important role in bone carcinogenesis and metastatic progression. This study investigated the diagnostic potential of the two main Wnt inhibitors, sclerostin and DKK-1, to improve the detection of osteolytic bone metastases. We measured sclerostin and DKK-1, MMP-2 and MMP-9, the bone resorption marker TRAP5b and the metastatic marker survivin in a control group of healthy patients, in patients with primary tumors and in a group with metastasis. Sclerostin and DKK-1 were clearly high in primary tumor patients and even higher in metastatic patients, compared to controls. The close correlations with metastatic markers and bone resorption markers make sclerostin and DKK-1 promising as new biomarkers in the diagnosis of bone osteolytic metastases.

AB - Despite the clinical importance of bone metastases, we still know little about their onset and progression and current diagnostic tools lack the sensitivity and specificity required for clear early diagnosis. We therefore need to continue studying the pathogenesis of bone metastatic invasion in order to improve diagnosis. The Wnt pathway has been described as having an important role in bone carcinogenesis and metastatic progression. This study investigated the diagnostic potential of the two main Wnt inhibitors, sclerostin and DKK-1, to improve the detection of osteolytic bone metastases. We measured sclerostin and DKK-1, MMP-2 and MMP-9, the bone resorption marker TRAP5b and the metastatic marker survivin in a control group of healthy patients, in patients with primary tumors and in a group with metastasis. Sclerostin and DKK-1 were clearly high in primary tumor patients and even higher in metastatic patients, compared to controls. The close correlations with metastatic markers and bone resorption markers make sclerostin and DKK-1 promising as new biomarkers in the diagnosis of bone osteolytic metastases.

UR - http://www.scopus.com/inward/record.url?scp=84989775162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989775162&partnerID=8YFLogxK

M3 - Article

C2 - 27358126

AN - SCOPUS:84989775162

VL - 30

SP - 399

EP - 408

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -